Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer

Abstract The fusion event between EML4 and ALK drives a significant oncogenic activity in 5% of non-small cell lung cancer (NSCLC). Even though potent ALK-tyrosine kinase inhibitors (ALK-TKIs) are successfully used for the treatment of EML4-ALK-positive NSCLC patients, a subset of those patients eve...

Full description

Saved in:
Bibliographic Details
Main Authors: Josephina Sampson, Hyun-min Ju, Nan Zhang, Sharon Yeoh, Jene Choi, Richard Bayliss
Format: Article
Language:English
Published: Nature Publishing Group 2024-12-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-024-07272-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items